- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05607446
To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis
November 1, 2022 updated by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Single-center, Randomized, Double-blind, Two-cycle, Two-way Crossover Phase Ib Study to Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis
A clinical study to evaluate the efficacy and safety of tqc3564 tablets in the treatment of persistent allergic rhinitis.
A total of 24 patients will be enrolled.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhi hai Xie, Doctor
- Phone Number: +86 15111013198
- Email: xiedoctor@126.com
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Recruiting
- Xiangya Hospital Central South University
-
Contact:
- Zhi hai Xie, Doctor
- Phone Number: 15111013198
- Email: xiedoctor@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18~65 years old, male or female;
Meet the clinical diagnostic criteria for allergic rhinitis, and the diagnosis is based on the "Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2015, Tianjin)" issued by the Rhinology Group of the Otolaryngology Head and Neck Surgery Branch of the Chinese Medical Association:
- Symptoms: sneezing 2 or more symptoms, such as watery mucus, nasal itching and nasal congestion, persist or accumulate for more than 1 hour per day, and may be accompanied by eye symptoms such as itching, watering and redness;
- Signs: Pale and edema of the nasal mucosa is common. Nasal watery secretions;
- Allergen test: at least one allergen SPT and/or serum-specific IgE positive (test results within 12 months before screening);
- Female subjects of childbearing age should agree to use contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; negative serum pregnancy test within 14 days before study enrollment , and must be non-lactating subjects; male subjects should agree to use contraception during the study period and for 6 months after the end of the study period.
- The subjects voluntarily joined the study, signed the informed consent, and had good compliance.
Exclusion Criteria:
- Patients with non-allergic rhinitis, such as drug-induced rhinitis, vasomotor rhinitis, non-allergic rhinitis eosinophilic rhinitis, etc.; patients with severe nasal septum deviation, sinusitis, nasal polyps, hypertrophic rhinitis Other nasal organic lesions;
- In the nasal examination at the end of the screening period or the introduction period, there is any erosion of the nasal mucosa, septal ulcer or perforation of the nasal septum;
- Those who have undergone sinus surgery within 3 months before the screening period or who have not fully healed the nasal wound;
- The subject has uncontrolled diabetes mellitus, that is, fasting blood glucose (FBG) > 10mmol/L in the laboratory test during the screening period;
- History of allergy to any study drug or similar chemical drugs (CRTh2 antagonists);
- History of severe allergic reaction to any allergen, such as anaphylactic shock or life-threatening asthma, previous intubation, respiratory arrest, hospitalization for asthma or acute asthma attack within the past 3 months;
- Those who were found to respond to placebo during the lead-in period (with rhinitis symptoms of moderate or above during the screening period, those with mild or no symptoms during the lead-in period, or baseline rTNSS mean <6 points were defined as placebo responders;
- Women who are pregnant or breastfeeding, or who plan to become pregnant or breastfeeding during the study period;
- Any subject deemed unsuitable for participation in this clinical study by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TQC3564 tablets
Orally administer TQC3564 tablets for 14 days.
|
TQC3564 tablets are CRTH2 antagonists.
|
Placebo Comparator: placebo tablets
Orally administer placebo tablets for 14 days.
|
The intervention drug is placebo.
|
Experimental: TQC3564 tablets + montelukast sodium tablets
Orally administer TQC3546 tablets combined with Montelukast sodium tablets for 14 days.
|
The intervention drugs are TQC3564 tablets combined with montelukast sodium tablets.
TQC3564 is a CRTH2 antagonist, montelukast sodium is Leukotriene receptor antagonist.
|
Placebo Comparator: placebo tablets + montelukast sodium tablets
Orally administer placebo tablets combined with Montelukast sodium tablets for 14 days.
|
The intervention drugs are placebo combined with montelukast sodium tablets.
Montelukast sodium is Leukotriene receptor antagonist.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total nasal symptom Score (TNSS)
Time Frame: Baseline, Day 14
|
Change in the investigator-assessed total nasal symptom score (TNSS) from baseline to 14 days.
TNSS was the sum score of 4 nasal symptoms with a minimum score of 0 units and a maximum score of 12 units, with higher score corresponding to increased nasal allergy symptoms.
|
Baseline, Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total ocular symptom score(TOSS)
Time Frame: Baseline, Day 14
|
Change in the TOSS from baseline to14 days.
TOSS was the sum of 2 ocular symptoms with a minimum score of 0 units and amaximum score of 6 units, with higher score corresponding to increased ocular symptoms.
|
Baseline, Day 14
|
Individual Total Nasal Symptom Score (TNSS)
Time Frame: Baseline, Day 14
|
Change in the individual TNSS from baseline to 14 days.
Individual nasal symptoms were each rated on a 4-point scale from 0-3 (0=Absent, 1=Mild, 2=Moderate, 3=Severe), with no half-unit assessments.
|
Baseline, Day 14
|
Individual Total Ocular Symptom Score (TOSS)
Time Frame: Baseline, Day 14
|
Change in the individual TOSS from baseline to 14 days.
Individual ocular symptoms were each rated on a 4-point scale from 0-3 (0=Absent, 1=Mild, 2=Moderate, 3=Severe), with no half-unit assessments.
|
Baseline, Day 14
|
Daily symptoms score (dSS)
Time Frame: Baseline, Day 14
|
Change in the dSS from baseline to 14 days.
dSS was the sum of 4 nasal symptoms and 2 ocular symptoms with a minimum score of 0 units and amaximum score of 18 units, with higher score corresponding to increased overall symptoms.
|
Baseline, Day 14
|
Rescue medication proportion
Time Frame: Day 1-32
|
Proportion of participants using rescue medication mometasone furoate nasal spray during intervention
|
Day 1-32
|
Rescue medication frequency
Time Frame: Day 1-32
|
Frequency of using rescue medication mometasone furoate nasal spray during intervention
|
Day 1-32
|
Incidence of adverse events
Time Frame: Day 1-32
|
Incidence of adverse events, including vital signs, physical examination, abnormal laboratory parameters, etc.,
|
Day 1-32
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 14, 2022
Primary Completion (Anticipated)
October 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
October 16, 2022
First Submitted That Met QC Criteria
November 1, 2022
First Posted (Actual)
November 7, 2022
Study Record Updates
Last Update Posted (Actual)
November 7, 2022
Last Update Submitted That Met QC Criteria
November 1, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Otorhinolaryngologic Diseases
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Rhinitis
- Rhinitis, Allergic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Asthmatic Agents
- Respiratory System Agents
- Leukotriene Antagonists
- Hormone Antagonists
- Cytochrome P-450 CYP1A2 Inducers
- Cytochrome P-450 Enzyme Inducers
- Montelukast
Other Study ID Numbers
- TQC3564-Ib-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinitis
-
Universitaire Ziekenhuizen KU LeuvenAZ Sint-Jan AVRecruitingPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis | Local Allergic RhinitisBelgium
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
ALK-Abelló A/SCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Humanis Saglık Anonim SirketiCompletedPerennial Allergic Rhinitis | Seasonal Allergic RhinitisIndia
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
Organon and CoCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
-
West Penn Allegheny Health SystemPennsylvania Allergy and Asthma Research FoundationCompletedAllergy | Perennial Allergic Rhinitis | Seasonal Allergic RhinitisUnited States
-
Ahn-Gook Pharmaceuticals Co.,LtdSamsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaboratorsCompletedAllergic Rhinitis | Perennial Allergic Rhinitis | Non-seasonal Allergic RhinitisKorea, Republic of
-
United Allergy ServicesCompletedPerennial Allergic Rhinitis With Seasonal VariationUnited States
Clinical Trials on TQC3564 tablets
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam
-
Cara Therapeutics, Inc.RecruitingPruritus | Notalgia ParestheticaUnited States, Poland, Spain, Canada, Germany
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedInflammatory Bowel DiseasesChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu vcare pharmaceutical technology co., LTDRecruitingModerate to Severe Atopic DermatitisChina
-
Shenzhen NewDEL Biotech, Co., LtdShenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.Enrolling by invitation
-
Akros Pharma Inc.CompletedSkin Diseases | Psoriasis | Plaque PsoriasisUnited States, Canada, Poland